abrocitinib vs bdb
Mechanistic comparison of abrocitinib and bdb us9663526 example 36 us10463675 example 36 us10980815 ex no 36 us11197867 exampl based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
4
Shared Targets
67%
Jaccard Similarity
69%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
Evidence Comparison
Target Overlap
abrocitinib and bdb share 4 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.667 means 67% of the combined target set is bound by both compounds. The IDF-weighted score of 0.686 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.